2nd Apr 2012 17:17
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
I give below details of changes in the directors' interests in the Ordinary Shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.
On 30 March 2012, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £14.07 per Ordinary Share, and notional ADSs at a price of $45.10 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 January 2012 to 31 March 2012:
Non Executive Director | Ordinary Shares | American Depositary Shares (ADSs) |
Sir Christopher Gent | 2,398.721 | |
Professor Sir Roy Anderson | 466.418 | |
Dr Stephanie Burns | 588.118 | |
Stacey Cartwright | 333.156 | |
Lawrence Culp | 914.850 | |
Sir Crispin Davis | 1,687.989 | |
Judy Lewent | 294.059 | |
Sir Deryck Maughan | 1,176.236 | |
James Murdoch | 1,332.623 | |
Dr Daniel Podolsky | 1,078.216 | |
Tom de Swaan | 688.522 | |
Sir Robert Wilson | 466.418 |
The Company and the Non-Executive Directors were informed of these allocations on 2 April 2012.
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
V A Whyte
Company Secretary
2 April 2012
Related Shares:
Glaxosmithkline